Figure 1.
Schematic view of miR-146a and miR-181b microRNAs delivered by E-selectin thioaptamer-multistage vector for treatment of atherosclerosis. CCL2: monocyte chemoattractant protein-1
Figure 2.
Effects of PEG/PEI/micro-RNAs and ESTA-MSV/microRNAs on the aortic atherogenesis of apolipoprotein E-deficient (ApoE−/−) mice. (A) Representative en face Oil Red O-stained aortic arches and thoracic aortae of ApoE−/− mice intravenously injected with vehicle, miR-146a, and miR-181b (15 μg) loaded in PEG/PEI nanoparticles or (C) ESTA-MSV microparticles biweekly for 12 weeks. (B, D) Quantification of en face aortic plaque size. * P < 0.05, **P < 0.01 vs vehicle group. Adapted from Ma et al.51 ESTA-MSV: E-selectin thioaptamer-multistage vector; PEG-PEI: polyethylene glycol-polyethyleneimine